Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review

CONTEXT: Immune-checkpoint inhibitors (ICI) have shown significant benefits for overall survival across various cancer types. Patient-reported outcomes (PROs) are assessed in clinical trials as a measure of efficacy. However, it remains unclear to what extent current PRO instruments capture symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomer-Lahiguera, Sara, Bryant-Lukosius, Denise, Rietkoetter, Sarah, Martelli, Lorraine, Ribi, Karin, Fitzpatrick-Lewis, Donna, Sherifali, Diana, Orcurto, Angela, Juergens, Rosalyn, Eicher, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364679/
https://www.ncbi.nlm.nih.gov/pubmed/32676785
http://dx.doi.org/10.1186/s41687-020-00210-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364679/
https://www.ncbi.nlm.nih.gov/pubmed/32676785
http://dx.doi.org/10.1186/s41687-020-00210-z

Ejemplares similares